The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
Fragment-Based Lead Discovery and Design
Abstract
Fragment-based lead discovery and design has and continues to show increasing promise in drug discovery. In this article, the current state of the art in terms of hot-spot characterization, fragment screening techniques, and fragment-based design is discussed. Three overall fragment-based lead generation strategies are explored and involve the chemical biology characterization of biological targets via fragment screening, fragment screening as a complementary approach to high-throughput screening of drug-like compounds, and direct fragment-based drug discovery, respectively. The evolution and development of fragment libraries is described. With an emphasis on computational approaches and the strategies applied at AstraZeneca, the review illustrates how integration of data from one regime can inform the design of experiments in the other, ultimately leading to the discovery of high quality chemical matter.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“With covalent inhibition, the drug action time mainly depends on protein turnover time, rather than other pharmacokinetic properties [119].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [119]
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Goodford, P. J. (1985) · Journal of Medicinal Chemistry · doi:10.1021/jm00145a002 · Cited by 2,634
Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512
The Properties of Known Drugs. 1. Molecular Frameworks
Bemis, G. W., & Murcko, M. A. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm9602928 · Cited by 2,482
Pervushin, K., Riek, R., Wider, G., & Wüthrich, K. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.23.12366 · Cited by 2,445
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Discovering High-Affinity Ligands for Proteins: SAR by NMR
Shuker, S. B., Hajduk, P. J., Meadows, R. P., & Fesik, S. W. (1996) · Science · doi:10.1126/science.274.5292.1531 · Cited by 2,041
Anatomy of hot spots in protein interfaces
Bogan, A. A., & Thorn, K. S. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.1843 · Cited by 1,988
Ligand efficiency: a useful metric for lead selection
Hopkins, A. L., Groom, C. R., & Alex, A. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03069-7 · Cited by 1,846
Characterization of Ligand Binding by Saturation Transfer Difference NMR Spectroscopy
Mayer, M., & Meyer, B. (1999) · Angewandte Chemie International Edition · doi:10.1002/(sici)1521-3773(19990614)38:12<1784::aid-anie1784>3.0.co;2-q · Cited by 1,595
Principles of Nuclear Magnetic Resonance in One and Two Dimensions
Ernst, R. R., Bodenhausen, G., & Wokaun, A. (1990) · doi:10.1093/oso/9780198556473.001.0001 · Cited by 1,418
A ‘Rule of Three’ for fragment-based lead discovery?
Congreve, M., Carr, R., Murray, C., & Jhoti, H. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02831-9 · Cited by 1,354
Mayer, M., & Meyer, B. (2001) · Journal of the American Chemical Society · doi:10.1021/ja0100120 · Cited by 1,200
A decade of fragment-based drug design: strategic advances and lessons learned
Hajduk, P. J., & Greer, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2220 · Cited by 1,064
Navigating chemical space for biology and medicine
Lipinski, C., & Hopkins, A. (2004) · Nature · doi:10.1038/nature03193 · Cited by 1,002
Computer-based de novo design of drug-like molecules
Schneider, G., & Fechner, U. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1799 · Cited by 948
On the attribution and additivity of binding energies
Jencks, W. P. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.7.4046 · Cited by 912
Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery
Hann, M. M., Leach, A. R., & Harper, G. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci000403i · Cited by 877
The Design of Leadlike Combinatorial Libraries
Teague, S. J., Davis, A. M., Leeson, P. D., & Oprea, T. (1999) · Angewandte Chemie International Edition · doi:10.1002/(sici)1521-3773(19991216)38:24<3743::aid-anie3743>3.0.co;2-u · Cited by 870
970 Million Druglike Small Molecules for Virtual Screening in the Chemical Universe Database GDB-13
Blum, L. C., & Reymond, J.-L. (2009) · Journal of the American Chemical Society · doi:10.1021/ja902302h · Cited by 860
The maximal affinity of ligands
Kuntz, I. D., Chen, K., Sharp, K. A., & Kollman, P. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.9997 · Cited by 849
Rees, D. C., Congreve, Murray, C. W., & Carr, R. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1467 · Cited by 798
Lyne, P. D., Lamb, M. L., & Saeh, J. C. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060522a · Cited by 699
WaterLOGSY as a method for primary NMR screening: Practical aspects and range of applicability
Dalvit, C., Fogliatto, G., Stewart, A., Veronesi, M., & Stockman, B. (2001) · Journal of Biomolecular NMR · doi:10.1023/a:1013302231549 · Cited by 562
A Comparison of Physiochemical Property Profiles of Development and Marketed Oral Drugs
Wenlock, M. C., Austin, R. P., Barton, P., Davis, A. M., & Leeson, P. D. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm021053p · Cited by 546
Functionality maps of binding sites: A multiple copy simultaneous search method
Miranker, A., & Karplus, M. (1991) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.340110104 · Cited by 544
Functional group contributions to drug-receptor interactions
Andrews, P. R., Craik, D. J., & Martin, J. L. (1984) · Journal of Medicinal Chemistry · doi:10.1021/jm00378a021 · Cited by 535
Ligand efficiency indices as guideposts for drug discovery
Abad-Zapatero, C., & Metz, J. T. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03386-6 · Cited by 527
Druggability Indices for Protein Targets Derived from NMR-Based Screening Data
Hajduk, P. J., Huth, J. R., & Fesik, S. W. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049131r · Cited by 522
Site-directed ligand discovery
Erlanson, D. A., Braisted, A. C., Raphael, D. R., Randal, M., Stroud, R. M., Gordon, E. M., & Wells, J. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.17.9367 · Cited by 466
LUDI: rule-based automatic design of new substituents for enzyme inhibitor leads
B�hm, H.-J. (1992) · Journal of Computer-Aided Molecular Design · doi:10.1007/bf00126217 · Cited by 459
Fink, T., & Reymond, J.-L. (2007) · Journal of Chemical Information and Modeling · doi:10.1021/ci600423u · Cited by 457
Brenke, R., Kozakov, D., Chuang, G.-Y., Beglov, D., Hall, D., Landon, M. R., Mattos, C., & Vajda, S. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp036 · Cited by 455
Brough, P. A., Aherne, W., Barril, X., Borgognoni, J., Boxall, K., Cansfield, J. E., Cheung, K.-M. J., Collins, I., Davies, N. G. M., Drysdale, M. J., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701018h · Cited by 444
Fragment-Based Lead Discovery Using X-ray Crystallography
Hartshorn, M. J., Murray, C. W., Cleasby, A., Frederickson, M., Tickle, I. J., & Jhoti, H. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0495778 · Cited by 422
Tethering: Fragment-Based Drug Discovery
Erlanson, D. A., Wells, J. A., & Braisted, A. C. (2004) · Annual Review of Biophysics and Biomolecular Structure · doi:10.1146/annurev.biophys.33.110502.140409 · Cited by 385
Hajduk, P. J., Olejniczak, E. T., & Fesik, S. W. (1997) · Journal of the American Chemical Society · doi:10.1021/ja9715962 · Cited by 371
Characteristic Physical Properties and Structural Fragments of Marketed Oral Drugs
Vieth, M., Siegel, M. G., Higgs, R. E., Watson, I. A., Robertson, D. H., Savin, K. A., Durst, G. L., & Hipskind, P. A. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030267j · Cited by 359
Fragment-based lead discovery: leads by design
Carr, R. A. E., Congreve, M., Murray, C. W., & Rees, D. C. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03511-7 · Cited by 343
Howard, S., Berdini, V., Boulstridge, J. A., Carr, M. G., Cross, D. M., Curry, J., Devine, L. A., Early, T. R., Fazal, L., Gill, A. L., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm800984v · Cited by 333
Discovering novel ligands for macromolecules using X-ray crystallographic screening
Nienaber, V. L., Richardson, P. L., Klighofer, V., Bouska, J. J., Giranda, V. L., & Greer, J. (2000) · Nature Biotechnology · doi:10.1038/80319 · Cited by 322
Ligand Binding Efficiency: Trends, Physical Basis, and Implications
Reynolds, C. H., Tounge, B. A., & Bembenek, S. D. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701255b · Cited by 319
The SHAPES strategy: an NMR-based approach for lead generation in drug discovery
Fejzo, J., Lepre, C. A., Peng, J. W., Bemis, G. W., Ajay, Murcko, M. A., & Moore, J. M. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(00)80022-8 · Cited by 271
Ryckmans, T., Edwards, M. P., Horne, V. A., Correia, A. M., Owen, D. R., Thompson, L. R., Tran, I., Tutt, M. F., & Young, T. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.05.062 · Cited by 270
Route to three-dimensional fragments using diversity-oriented synthesis
Hung, A. W., Ramek, A., Wang, Y., Kaya, T., Wilson, J. A., Clemons, P. A., & Young, D. W. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015271108 · Cited by 268
CAVEAT: A program to facilitate the design of organic molecules
Lauri, G., & Bartlett, P. A. (1994) · Journal of Computer-Aided Molecular Design · doi:10.1007/bf00124349 · Cited by 266
Developing a Dynamic Pharmacophore Model for HIV-1 Integrase
Carlson, H. A., Masukawa, K. M., Rubins, K., Bushman, F. D., Jorgensen, W. L., Lins, R. D., Briggs, J. M., & McCammon, J. A. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990322h · Cited by 259
Molecular docking and ligand specificity in fragment-based inhibitor discovery
Chen, Y., & Shoichet, B. K. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.155 · Cited by 252
Enzyme crystal structure in a neat organic solvent.
Fitzpatrick, P. A., Steinmetz, A. C., Ringe, D., & Klibanov, A. M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.18.8653 · Cited by 229
Stoichiometry and Physical Chemistry of Promiscuous Aggregate-Based Inhibitors
Coan, K. E. D., & Shoichet, B. K. (2008) · Journal of the American Chemical Society · doi:10.1021/ja802977h · Cited by 225
Edwards, P. D., Albert, J. S., Sylvester, M., Aharony, D., Andisik, D., Callaghan, O., Campbell, J. B., Carr, R. A., Chessari, G., Congreve, M., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070829p · Cited by 214
Stumpfe, D., Hu, Y., Dimova, D., & Bajorath, J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401120g · Cited by 211
Eisen, M. B., Wiley, D. C., Karplus, M., & Hubbard, R. E. (1994) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.340190305 · Cited by 210
de Graaf, C., Kooistra, A. J., Vischer, H. F., Katritch, V., Kuijer, M., Shiroishi, M., Iwata, S., Shimamura, T., Stevens, R. C., de Esch, I. J. P., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2011589 · Cited by 204
From fragment to clinical candidate—a historical perspective
Chessari, G., & Woodhead, A. J. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.04.007 · Cited by 202
SuperStar: A Knowledge-based Approach for Identifying Interaction Sites in Proteins
Verdonk, M. L., Cole, J. C., & Taylor, R. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.2809 · Cited by 198
Cai, M., Huang, Y., Sakaguchi, K., Clore, G. M., Gronenborn, A. M., & Craigie, R. (1998) · Journal of Biomolecular NMR · doi:10.1023/a:1008222131470 · Cited by 197
An Experimental Approach to Mapping the Binding Surfaces of Crystalline Proteins
Allen, K. N., Bellamacina, C. R., Ding, X., Jeffery, C. J., Mattos, C., Petsko, G. A., & Ringe, D. (1996) · The Journal of Physical Chemistry · doi:10.1021/jp952516o · Cited by 186
Pierce, A. C., Rao, G., & Bemis, G. W. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030543u · Cited by 185
Transforming fragments into candidates: small becomes big in medicinal chemistry
de Kloe, G. E., Bailey, D., Leurs, R., & de Esch, I. J. P. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.03.009 · Cited by 178
Brough, P. A., Barril, X., Borgognoni, J., Chene, P., Davies, N. G. M., Davis, B., Drysdale, M. J., Dymock, B., Eccles, S. A., Garcia-Echeverria, C., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900357y · Cited by 173
Molecular complexity and fragment-based drug discovery: ten years on
Leach, A. R., & Hann, M. M. (2011) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2011.05.008 · Cited by 169
Fragment screening: an introduction
Leach, A. R., Hann, M. M., Burrows, J. N., & Griffen, E. J. (2006) · Molecular BioSystems · doi:10.1039/b610069b · Cited by 163
Fragment-based lead discovery: a chemical update
Erlanson, D. A. (2006) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2006.10.007 · Cited by 149
Fragment-Based de Novo Ligand Design by Multiobjective Evolutionary Optimization
Dey, F., & Caflisch, A. (2008) · Journal of Chemical Information and Modeling · doi:10.1021/ci700424b · Cited by 148
Discovery of a Novel Warhead against β-Secretase through Fragment-Based Lead Generation
Geschwindner, S., Olsson, L., Albert, J. S., Deinum, J., Edwards, P. D., de Beer, T., & Folmer, R. H. A. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070825k · Cited by 146
Eakin, A. E., Green, O. M., Hales, N. J., Walkup, G. K., Bist, S., Singh, A., MULLEN, G. B., Bryant, J., Embrey, K. J., Gao, N., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05485-11 · Cited by 142
Maaß, P. C., Schulz‐Gasch, T., Ståhl, M., & Rarey, M. (2007) · Journal of Chemical Information and Modeling · doi:10.1021/ci060094h · Cited by 141
Baurin, N., Aboul‐ela, F., Barril, X., Davis, B. J., Drysdale, M., Dymock, B. W., Finch, H., Fromont, C., Richardson, C. M., Simmonite, H., et al. (2004) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci049806z · Cited by 135
Application of Fragment Screening and Fragment Linking to the Discovery of Novel Thrombin Inhibitors
Howard, N., Abell, C., Blakemore, W. E., Chessari, G., Congreve, M., Howard, S., Jhoti, H., Murray, C. W., Seavers, L. C. A., & van Montfort, R. L. M. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm050850v · Cited by 134
Gillet, V. J., Myatt, G. J., Zsoldos, Z., & Johnson, A. P. (1995) · Perspectives in Drug Discovery and Design · doi:10.1007/bf02174466 · Cited by 131
Investigation of MM-PBSA Rescoring of Docking Poses
Thompson, D. C., Humblet, C. C., & Joseph‐McCarthy, D. (2008) · Journal of Chemical Information and Modeling · doi:10.1021/ci700470c · Cited by 129
Self-citationAlbert, J. S., Blomberg, N., Breeze, A. L., Brown, A., Burrows, J. N., Edwards, P. D., Folmer, R. H. A., Geschwindner, S., Griffen, E., Kenny, P. W., et al. (2007) · Current Topics in Medicinal Chemistry · doi:10.2174/156802607782341091 · Cited by 126
Baurin, N., Baker, R., Richardson, C., Chen, I., Foloppe, N., Potter, A., Jordan, A. M., Roughley, S. D., Parratt, M. J., Greaney, P., et al. (2004) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci034260m · Cited by 123
Small Molecule Shape-Fingerprints
Haigh, J. A., Pickup, B. T., Grant, J., et al. (2005) · Journal of Chemical Information and Modeling · doi:10.1021/ci049651v · Cited by 116
CONCERTS: Dynamic Connection of Fragments as an Approach to de Novo Ligand Design
Pearlman, D. A., & Murcko, M. A. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm950792l · Cited by 116
Imai, T., Oda, K., Kovalenko, A., Hirata, F., & Kidera, A. (2009) · Journal of the American Chemical Society · doi:10.1021/ja905029t · Cited by 112
Assessing the lipophilicity of fragments and early hits
Mortenson, P. N., & Murray, C. W. (2011) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-011-9435-z · Cited by 112
Hajduk, P. J., Galloway, W. R. J. D., & Spring, D. R. (2011) · Nature · doi:10.1038/470042a · Cited by 111
Computational Approaches for Fragment-Based and De Novo Design
Loving, K. A., Alberts, I. L., & Sherman, W. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610790232305 · Cited by 111
Docking for fragment inhibitors of AmpC β-lactamase
Teotico, D. G., Babaoglu, K., Rocklin, G. J., Ferreira, R. S., Giannetti, A. M., & Shoichet, B. K. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813029106 · Cited by 102
Kawatkar, S. P., Wang, H., Czermiński, R., & Joseph‐McCarthy, D. (2009) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-009-9281-4 · Cited by 101
Self-citationScreening for GPCR Ligands Using Surface Plasmon Resonance
Navratilova, I. H., Besnard, J., & Hopkins, A. L. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml2000017 · Cited by 95
Becattini, B., Culmsee, C., Leone, M., Zhai, D., Zhang, X., Crowell, K. J., Rega, M. F., Landshamer, S., Reed, J. C., Plesnila, N., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603460103 · Cited by 94
Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discovery
Erlanson, D. A., Arndt, J. W., Cancilla, M. T., Cao, K., Elling, R. A., English, N., Friedman, J., Hansen, S. K., Hession, C., Joseph, I. B. J., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.03.032 · Cited by 91
Baurin, N., Mozziconacci, J., Arnoult, É., Chavatte, P., Marot, C., & Morin‐Allory, L. (2003) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci0341565 · Cited by 85
Landon, M. R., Lieberman, R. L., Hoang, Q. Q., Ju, S., Caaveiro, J. M. M., Orwig, S. D., Kozakov, D., Brenke, R., Chuang, G., Beglov, D., et al. (2009) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-009-9283-2 · Cited by 84
Fragment-based discovery of JAK-2 inhibitors
Antonysamy, S., Hirst, G. C., Park, F., Sprengeler, P. A., Stappenbeck, F., Steensma, R. W., Wilson, M., & Wong, M. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.08.064 · Cited by 83
Pharmacophore‐based molecular docking to account for ligand flexibility
Joseph‐McCarthy, D., Thomas, B. E., Belmarsh, M., Moustakas, D. T., & Alvarez, J. C. (2003) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.10266 · Cited by 80
Self-citationSledz, P., Silvestre, H. L., Hung, A. W., Ciulli, A., Blundell, T. L., & Abell, C. (2010) · Journal of the American Chemical Society · doi:10.1021/ja100595u · Cited by 78
Design of compound libraries for fragment screening
Blomberg, N., Cosgrove, D. A., Kenny, P. W., & Kolmodin, K. (2009) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-009-9264-5 · Cited by 77
Tanaka, D., Tsuda, Y., Shiyama, T., Nishimura, T., Chiyo, N., Tominaga, Y., Sawada, N., Mimoto, T., & Kusunose, N. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm101273e · Cited by 74
Correction for Interference by Test Samples in High-Throughput Assays
Shapiro, A. B., Walkup, G. K., & Keating, T. A. (2006) · SLAS DISCOVERY · doi:10.1177/1087057106286653 · Cited by 74
Perrin, D., Frémaux, C., & Scheer, A. (2006) · SLAS DISCOVERY · doi:10.1177/1087057109341768 · Cited by 68
Lead optimization via high-throughput molecular docking.
Joseph‐McCarthy, D., Baber, J. C., Feyfant, E., Thompson, D. C., & Humblet, C. C. (2007) · PubMed · Cited by 64
Self-citationThe INPHARMA technique for pharmacophore mapping: A theoretical guide to the method
Orts, J., Griesinger, C., & Carlomagno, T. (2009) · Journal of Magnetic Resonance · doi:10.1016/j.jmr.2009.06.006 · Cited by 55
Drug Design for G‐Protein‐Coupled Receptors by a Ligand‐Based NMR Method
Bartoschek, S., Klabunde, T., Defoßa, E., Dietrich, V., Stengelin, S., Griesinger, C., Carlomagno, T., Focken, I., & Wendt, K. U. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200905102 · Cited by 51
Computational Fragment-Based Approach at PDB Scale by Protein Local Similarity
Moriaud, F., Doppelt‐Azeroual, O., Martin, L., Oguievetskaia, K., Koch, K., Vorotyntsev, A., Adcock, S. A., & Delfaud, F. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci8003094 · Cited by 50
Design of a Fragment Library that maximally represents available chemical space
Schulz, M. N., Landström, J., Bright, K., & Hubbard, R. E. (2011) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-011-9461-x · Cited by 44
“Virtual Fragment Linking”: An Approach To Identify Potent Binders from Low Affinity Fragment Hits
Crisman, T. J., Bender, A., Milik, M., Jenkins, J. L., Scheiber, J., Sukuru, S. C. K., Fejzo, J., Hommel, U., Davies, J. W., & Glick, M. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701314u · Cited by 44
Joseph‐McCarthy, D., & Alvarez, J. C. (2003) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.10296 · Cited by 40
Self-citationVerlinde, C. L. M. J., Fan, E., Shibata, S., Zhang, Z., Sun, Z., Deng, W., Ross, J., Kim, J. J., Xiao, L., Arakaki, T. L., et al. (2009) · Current Topics in Medicinal Chemistry · doi:10.2174/156802609790102383 · Cited by 38
CONFIRM: connecting fragments found in receptor molecules
Thompson, D. C., Denny, R. A., Nilakantan, R., Humblet, C. C., Joseph‐McCarthy, D., & Feyfant, E. (2008) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-008-9221-8 · Cited by 37
Self-citationPeptidoglycan structure of Enterococcus faecium expressing vancomycin resistance of the VanB type
Billot-Klein, D., Shlaes, D. M., Bryant, D. T. W., Bell, D., van HEIJENOORT, J., & Gutmann, L. (1996) · Biochemical Journal · doi:10.1042/bj3130711 · Cited by 33
Feyfant, E., Cross, J. B., Parris, K. D., & Tsao, D. H. H. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-931-4_12 · Cited by 31
Fragment-based lead discovery: challenges and opportunities
Sun, C. C., Petros, A. M., & Hajduk, P. J. (2011) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-011-9451-z · Cited by 30
A Novel Approach to Combinatorial Library Design
Nilakantan, R. (2002) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207024607310 · Cited by 27
Fragment Screening Purely with Protein Crystallography
Spurlino, J. C. (2011) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-381274-2.00013-3 · Cited by 26
Ligand design by a combinatorial approach based on modeling and experiment: application to HLA-DR4
Evensen, E., Joseph‐McCarthy, D., Weiss, G. A., et al. (2007) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-007-9119-x · Cited by 23
Self-citationStructural models in the assessment of protein druggability based on HTS data
Gupta, A., Gupta, A. K., & Seshadri, K. (2009) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-009-9279-y · Cited by 22
Fragment-based drug design: combining philosophy with technology.
Bartoli, S., Fincham, C. I., & Fattori, D. (2007) · PubMed · Cited by 22
Challenges of fragment screening
Joseph‐McCarthy, D. (2009) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-009-9293-0 · Cited by 14
Self-citationStauch, B., Orts, J., & Carlomagno, T. (2012) · Journal of Biomolecular NMR · doi:10.1007/s10858-012-9662-1 · Cited by 10
Seebeck, B., Wagener, M., & Rarey, M. (2011) · ChemMedChem · doi:10.1002/cmdc.201190037 · Cited by 1
Research works printed but not linked: 6
- Joseph-McCarthy D., 2007, Curr. Opin. Drug Discov. Devel., 10, 264
- Cavanagh, J.; Fairbrother, W. J.; Palmer, III, A. G.; Skelton, N.; Rance, M.Protein NMR Spectroscopy: Principles and Practice;Elsevier Science & Technology:Oxford/GB, 2006; p912.
- Bartoli S., 2007, Curr. Opin. Drug Discov. Devel., 10, 422
- Rawlins P., 2010, Drug Discov. World
- Davies T. G., 2011, Top. Curr. Chem., 1
- Nilakantan R., 2002, Comb. Chem. High Throughput Screen., 5, 105
Cited by
The design and development of covalent protein-protein interaction inhibitors for cancer treatment
Cheng, S.-S., Yang, G.-J., Wang, W., Leung, C.-H., & Ma, D.-L. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00850-0 · Cited by 98
Protein‐protein interactions as antibiotic targets: A medicinal chemistry perspective
Cossar, P. J., Lewis, P. J., & McCluskey, A. (2020) · Medicinal Research Reviews · doi:10.1002/med.21519 · Cited by 55
Metadata
- Authors
- Joseph-McCarthy, D., Campbell, A. J., Kern, G., & Moustakas, D.
- Affiliations
- Infection Innovative Medicines Unit, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States
- AstraZeneca (United States) (US)
- Venue
- Journal of Chemical Information and Modeling
- Publisher
- American Chemical Society (ACS)
- Published
- 2014-02-19
- Volume
- 54
- Issue
- 3
- Pages
- 693-704
- ISSN
- 1549-9596 (ISSN-L)
- 1549-960X
- OpenAlex
- W2090936831
- Cited by
- 129
- References
- 114
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 8 · 2023: 5 · 2022: 7 · 2021: 4 · 2020: 11 · 2019: 15 · 2018: 12 · 2017: 19 · 2016: 22 · 2015: 17 · 2014: 7
- FWCI
- 1.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Chemical Information and Modeling (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- fragment-based drug discovery, fragment screening, fragment libraries, chemical biology, high-throughput screening, computer-aided drug design, AstraZeneca
- MeSH terms
- Animals, Humans, Magnetic Resonance Spectroscopy, Proteins, Crystallography, X-Ray, Surface Plasmon Resonance, Small Molecule Libraries, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.